Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Blood Purif. 2002;20(2):161-6.

Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients.

Author information

  • 1Directorate of Medicine, Gloucestershire Royal Hospital, Gloucester, UK.

Abstract

BACKGROUND:

Serum beta(2)-microglobulin (beta(2)M) levels are important in dialysis-related amyloid deposition but can be influenced by dialysis technique.

METHODS:

We measured beta(2)M levels in 3 centres using different dialysis regimes. Centre 1 (73 patients) used high-flux biocompatible, centre 2 (72 patients) low-flux biocompatible and centre 3 (142 patients) cuprophane dialysers.

RESULTS:

beta(2)M levels were lower with high-flux biocompatible than with low-flux biocompatible or cuprophane dialysis (22.3 +/- 5.4 vs. 43.4 +/-13.7 and 37.6 +/-13.1 mg/l, respectively; p < 0.001). Levels were higher with low-flux biocompatible than with cuprophane dialysis (p < 0.001), but not if patients dialysed over 10 years were excluded. With low-flux biocompatible (47.4 +/- 9.8 vs. 38.7 +/- 15.2 mg/l; p < 0.01) and cuprophane dialysis (43.4 +/- 8.2 vs. 36.7 +/- 13.0 mg/l; p < 0.02), beta(2)M levels were higher in patients dialysed over 5 years than in those dialysed less. Despite beta(2)M levels increasing as residual renal function declined, there was no similar rise with high-flux biocompatible dialysis.

CONCLUSIONS:

Techniques allowing significant convection maintain lower beta(2)M levels over many years. Membrane flux, not biocompatibility, is the main determinant of beta(2)M levels in routine practice.

Copyright 2002 S. Karger AG, Basel

PMID:
11818679
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk